Nitroxoline

Overview

Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a hydroxyquinoline derivative unrelated to other classes of drugs. Nitroxoline is active against bacterial gyrases.

Indication

Nitroxoline is an antibiotic agent.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1	2024/08/07	NCT06541847	Phase 2	Recruiting	Healx Limited
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers	2024/05/30	NCT06435039	Phase 1	Terminated	Syneos Health
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients	2021/02/03	NCT04736394	Phase 3	Recruiting	Jiangsu Yahong Meditech Co., Ltd aka Asieris
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment	2018/09/14	NCT03672240	Phase 1	Completed	Asieris Pharmaceutical Technologies Co., Ltd.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Healx Initiates Phase 2 Trial of AI-Discovered HLX-1502 for Neurofibromatosis Type 1 Treatment

5 months ago

• Healx has dosed the first patient in INSPIRE-NF1, a Phase 2 trial evaluating HLX-1502, an oral therapy discovered through AI technology, for treating neurofibromatosis type 1. • The investigational drug HLX-1502 has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, highlighting its potential as an alternative to current MEK inhibitors. • The trial will enroll approximately 20 patients with plexiform neurofibromas across U.S. centers, focusing on tumor response rate, safety, and pharmacokinetics.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access